Literature DB >> 33676411

Imaging analysis of 13 rare cases of renal collecting (Bellini) duct carcinoma in northern China: a case series and literature review.

Zhehao Lyu1, Lili Liu2, Huimin Li3, Haibo Wang4, Qi Liu5, Tingting Chen4, Meiling Xu4, Lin Tian6, Peng Fu7.   

Abstract

BACKGROUND: Collecting (Bellini) duct carcinoma (CDC) is a highly malignant and rare kidney tumor. We report our 12-year experience with CDC and the results of a retrospective analysis of patients and tumor characteristics, clinical manifestations, and imaging features by computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET)/CT.
METHODS: Retrospective examination of tumors between January 2007 and December 2019 identified 13 cases of CDC from three medical centers in northern China. All 13 patients underwent CT scan, among which eight underwent dynamic enhanced CT scan, two underwent PET/CT scan, and one underwent magnetic resonance cholangiopancreatography (MRCP) examination. The lesions were divided into nephritis type and mass type according to the morphology of the tumors.
RESULTS: The study group included ten men and three women with an average age of 64.23 ± 10.74 years. The clinical manifestations were gross hematuria, flank pain, and waist discomfort. The mean tumor size was 8.48 ± 2.48 cm. Of the 13 cases, six (46.2%) were cortical-medullary involved type and seven (53.8%) were cortex-medullary-pelvis involved type. Eleven (84.6%) cases were nephritis type and two (15.4%) were mass type. The lesions appeared solid or complex solid and cystic on CT and MRI. The parenchymal area of the tumors showed isodensity or slightly higher density on unenhanced CT scan in the 13 cases. PET/CT in two cases showed increased radioactivity intake. Evidence of intra-abdominal metastatic disease was present on CT in nine (69.2%) cases.
CONCLUSIONS: The imaging characteristics of CDC differ from those of other renal cell carcinomas. In renal tumors located in the junction zone of the renal cortex and medulla that show unclear borders, slight enhancement, and metastases in the early stage, a diagnosis of CDC needs to be considered. PET/CT provides crucial information for the diagnosis of CDC, as well as for designing treatment strategies including surgery.

Entities:  

Keywords:  Collecting (Bellini) duct carcinoma; Kidney neoplasms; Positron emission tomography computed tomography; Tomography scanners; X-ray computed

Mesh:

Year:  2021        PMID: 33676411      PMCID: PMC7937320          DOI: 10.1186/s12880-021-00574-8

Source DB:  PubMed          Journal:  BMC Med Imaging        ISSN: 1471-2342            Impact factor:   1.930


  30 in total

1.  The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

Authors:  John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  The distribution of cytokeratin antigens in the kidney and in renal tumours.

Authors:  S Fleming; C E Symes
Journal:  Histopathology       Date:  1987-02       Impact factor: 5.087

Review 3.  PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology.

Authors:  Katherine Zukotynski; Aaron Lewis; Kevin O'Regan; Heather Jacene; Christopher Sakellis; Katherine Krajewski; David Israel
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

4.  Differentiation of subtypes of renal cell carcinoma on helical CT scans.

Authors:  Jeong Kon Kim; Tae Kyoung Kim; Han Jong Ahn; Chung Soo Kim; Kyu-Rae Kim; Kyoung-Sik Cho
Journal:  AJR Am J Roentgenol       Date:  2002-06       Impact factor: 3.959

5.  Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma: Discrimination From Common Renal Cell Carcinoma Subtypes and Benign RCC Mimics on Multiphasic MDCT.

Authors:  Jonathan R Young; Jocelyn A Young; Daniel J A Margolis; Steven Sauk; James Sayre; Allan J Pantuck; Steven S Raman
Journal:  Acad Radiol       Date:  2017-05-18       Impact factor: 3.173

Review 6.  Review of collecting duct carcinoma with focus on clinical and pathobiological aspects.

Authors:  N Kuroda; M Toi; M Hiroi; H Enzan
Journal:  Histol Histopathol       Date:  2002-10       Impact factor: 2.303

7.  Clear cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic karyotypes.

Authors:  Steven C Sauk; Margaret S Hsu; Daniel J A Margolis; David S K Lu; Nagesh P Rao; Arie S Belldegrun; Allan J Pantuck; Steven S Raman
Journal:  Radiology       Date:  2011-10-24       Impact factor: 11.105

8.  Collecting duct carcinoma of the kidney: CT and pathologic correlation.

Authors:  Seong Kuk Yoon; Kyung Jin Nam; Seo-Hee Rha; Jeong Kon Kim; Kyoung-Sik Cho; Bohyun Kim; Kie Hwan Kim; Kyung-Ah Kim
Journal:  Eur J Radiol       Date:  2005-11-02       Impact factor: 3.528

9.  The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer.

Authors:  A Safaei; R Figlin; C K Hoh; D H Silverman; M Seltzer; M E Phelps; J Czernin
Journal:  Clin Nephrol       Date:  2002-01       Impact factor: 0.975

10.  Collecting duct carcinoma of the kidney: Imaging observations of a rare tumor.

Authors:  Yuxiao Hu; Guang-Ming Lu; Kai Li; Long-Jiang Zhang; Hong Zhu
Journal:  Oncol Lett       Date:  2013-12-06       Impact factor: 2.967

View more
  2 in total

1.  Incidence, Clinical Characteristics, and Survival of Collecting Duct Carcinoma of the Kidney: A Population-Based Study.

Authors:  Chaopeng Tang; Yulin Zhou; Silun Ge; Xiaoming Yi; Huichen Lv; Wenquan Zhou
Journal:  Front Oncol       Date:  2021-09-14       Impact factor: 6.244

Review 2.  Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease.

Authors:  Cristina Suarez; David Marmolejo; Augusto Valdivia; Rafael Morales-Barrera; Macarena Gonzalez; Joaquin Mateo; Maria Eugenia Semidey; David Lorente; Enrique Trilla; Joan Carles
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.